Who owns Equashield and how much did they pay?

Swedish private equity firm Nordic Capital bought a 25% stake in Equashield for $300 million in October 2022, valuing the medical device maker at $1.3 billion and marking Nordic Capital's first Israeli investment. Founder Eric Shem-Tov remained the largest shareholder.

What is Equashield's market share versus BD's PhaSeal?

Equashield says it was named the most-used closed system transfer device in the US for the eighth consecutive year as of May 2026, citing a Pharmacy Purchasing & Products survey showing it accounts for 44% of CSTDs in use, ahead of incumbent BD's PhaSeal.

How much revenue does Equashield generate?

Nordic Capital, Equashield's private equity owner, reported 2025 revenue of EUR 120 million as of an October 2025 portfolio update, with products sold across five continents and Equashield positioned as CSTD leader in the US, the largest global market.

Could AI replace what Equashield makes?

Unlikely soon: Equashield's core products are FDA 510(k)-cleared, CE-marked physical hardware (syringes, adapters) for hazardous drug handling, a regulated mechanical workflow that generative AI cannot clear or replace, as described in company materials dated January 2026.

Who are Equashield's biggest competitors?

Direct CSTD competitors include BD (PhaSeal), ICU Medical (ChemoClave, ChemoLock), and Simplivia Healthcare (Tevadaptor/Chemfort), per an industry overview dated July 2026. In pharmacy automation, Equashield's newer Mundus compounding line faces incumbents like BD and Omnicell.

Is Equashield a unicorn company?

Yes. Equashield was valued at $1.3 billion when Nordic Capital acquired a 25% stake for $300 million in October 2022, a valuation that CB Insights and TrueUp aggregator trackers still listed as of mid-2026 with no newer round disclosed.

United States · United States

Equashield

Equashield builds closed-system devices that block hazardous drug exposure.

Hard to displace

Assessed 29 July 2026 · Evidence as of 29 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 29 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: Nordic Capital's roughly four-year private-equity hold approaches a possible exit (IPO, secondary, or sale)

The call

Equashield leads the US closed-system drug-transfer market by a wide margin, held in place by regulatory clearances, patents, and hospital workflow lock-in.

Equashield makes equipment that hospitals and pharmacies use to safely prepare cancer drugs and other dangerous medicines without exposing workers to toxic fumes. The company has knocked BD's PhaSeal product out of the top spot by building better equipment and becoming woven into hospital workflows, backed by patents and FDA approval that take years for competitors to match. The big question is whether the company's current owners will sell it in the next few years, which could change its independence and strategy.

Why

AI pressure: None apparent. AI has little direct role in this hardware category; future automation like Mundus could add AI-driven compounding logic. Could AI do the core job? Unlikely.

Bigger players: BD (Becton, Dickinson). BD's PhaSeal and ICU Medical's ChemoLock remain live CSTD rivals, though Equashield holds 44% of the US market. Could a giant copy it? Probably.

What protects it. FDA 510(k) clearance, EU MDR CE marking, 53 patents, and hospital workflow lock-in tied to USP 800 compliance.

What would change this call

BD or ICU Medical launches a next-gen CSTD or automated-compounding platform. Would show incumbents are directly challenging Equashield's product lead.
Equashield's US CSTD share falls below 44% in next annual survey. Would show its 8-year market-leader trend is reversing.
Nordic Capital exits Equashield via IPO, sale, or secondary within the year. Would reveal actual valuation and ownership stability after a 4-year hold.

Key numbers

44% of US CSTD market, #1 for 8th straight year (2026-05-08)
$1.3 billion valuation after Nordic Capital's 25% buy (2022-10-06)
470 employees, up from ~140 in 2018 (2025-10-28)

Named risks

Nordic Capital's roughly 4-year hold (since Oct 2022) could trigger an exit event resetting ownership and equity terms. Severity: medium
Core revenue and 44% market-share figures are vendor- or PE-owner-disclosed, not independently audited. Severity: medium
Mundus automated compounding line is early-stage with only one confirmed US deployment as of Dec 2025, facing established incumbents. Severity: medium
Regulated hazardous-drug device category carries inherent liability exposure if a safety event were tied to product use. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
BD (PhaSeal)	losing to	Equashield claims 44% US CSTD share vs BD's PhaSeal, 8th straight year as of May 2026
ICU Medical	contesting	ChemoClave and ChemoLock lines compete directly with Equashield in CSTD market, per 2026 industry overview
Omnicell	contesting	Adjacent pharmacy automation incumbent as Equashield expands into compounding with Mundus HD, Dec 2025
Simplivia Healthcare	contesting	Israeli rival's Tevadaptor/Chemfort CSTD line competes for hospital contracts, per 2026 Wikipedia overview

Questions people ask

Who owns Equashield and how much did they pay?: Swedish private equity firm Nordic Capital bought a 25% stake in Equashield for $300 million in October 2022, valuing the medical device maker at $1.3 billion and marking Nordic Capital's first Israeli investment. Founder Eric Shem-Tov remained the largest shareholder.
What is Equashield's market share versus BD's PhaSeal?: Equashield says it was named the most-used closed system transfer device in the US for the eighth consecutive year as of May 2026, citing a Pharmacy Purchasing & Products survey showing it accounts for 44% of CSTDs in use, ahead of incumbent BD's PhaSeal.
How much revenue does Equashield generate?: Nordic Capital, Equashield's private equity owner, reported 2025 revenue of EUR 120 million as of an October 2025 portfolio update, with products sold across five continents and Equashield positioned as CSTD leader in the US, the largest global market.
Could AI replace what Equashield makes?: Unlikely soon: Equashield's core products are FDA 510(k)-cleared, CE-marked physical hardware (syringes, adapters) for hazardous drug handling, a regulated mechanical workflow that generative AI cannot clear or replace, as described in company materials dated January 2026.
Who are Equashield's biggest competitors?: Direct CSTD competitors include BD (PhaSeal), ICU Medical (ChemoClave, ChemoLock), and Simplivia Healthcare (Tevadaptor/Chemfort), per an industry overview dated July 2026. In pharmacy automation, Equashield's newer Mundus compounding line faces incumbents like BD and Omnicell.
Is Equashield a unicorn company?: Yes. Equashield was valued at $1.3 billion when Nordic Capital acquired a 25% stake for $300 million in October 2022, a valuation that CB Insights and TrueUp aggregator trackers still listed as of mid-2026 with no newer round disclosed.

Timeline

2026-05-08Named most-used US CSTD for 8th straight year, claims 44% US market share
2025-12-03Unveiled EQUASHIELD Safety Platform combining CSTD, Mundus HD and IV workflow software
2025-12Chartwell Pharmacy becomes first US facility to deploy Mundus Compounding System
2025-10-28Nordic Capital reports 470 employees and EUR 120 million 2025 revenue
2025Acquired a Canada-based CSTD distributor to build direct sales presence
2023-12-01Launched Mundus Mini HD automated compounding system
2022-10-06Nordic Capital buys 25% stake for $300 million at $1.3 billion valuation
2009-04Founded by Eric Shem-Tov and Marino Kriheli

Revision history

29 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

CACI International United Airlines Holdings State Farm Insurance